Table 2 Epidemiological, demographic, clinical, laboratory and mortality outcome information collected from medical records
From: An interpretable mortality prediction model for COVID-19 patients
Characteristics | Overall |
|---|---|
Age, mean (s.d.) (years) | 58.83 (16.46) |
Gender, n (%) | |
Male | 224 (59.7) |
Female | 151 (40.3) |
Epidemiological history, n (%) | |
Wuhan residents | 142 (37.9) |
Contact with confirmed or suspected patients | 2 (0.5) |
Familial cluster | 24 (6.4) |
Health worker | 7 (1.9) |
Contact with Huanan Seafood Market | 2 (0.5) |
Undefined contact history | 198 (52.8) |
Symptoms on onset, n (%) | |
Fever | 187 (49.9) |
Cough | 52 (13.9) |
Fatigue | 14 (3.7) |
Dyspnoea | 8 (2.1) |
Chest distress | 7 (1.9) |
Muscular soreness | 2 (0.5) |
Outcomes, n (%) | |
Survival rate | 201 (53.6) |
Mortality rate | 174 (46.4) |
Laboratory test (patient’s last measurements) | |
LDH, median (range, Q1–Q3) (U l–1) | 273.50 (199.00, 617.75) |
Lymphocytes, median (range, Q1–Q3) (%) | 14.35 (4.17, 27.53) |
High-sensitivity C-reactive protein (mg l–1) | 26.3 (2.0, 99.10) |
Sodium median (range, Q1–Q3) (mmol l–1) | 140.7 (138.3, 143.3) |
Chlorine median (range, Q1–Q3) (mmol l–1) | 102.3 (99.53, 105.58) |
International normalized ratio (range, Q1–Q3) | 1.10 (1.02, 1.30) |
Eosinophils, median (range, Q1–Q3) (×109 l–1) | 0.02 (0.00, 0.09) |
Eosinophils, median (range, Q1–Q3) (%) | 0.25 (0.00, 1.50) |
Monocytes, median (range, Q1–Q3) (%) | 6.25 (2.98, 8.90) |
Albumin, mean (s.d.) (g l–1) | 32.67 (6.31) |
